Heron Therapeutics (NASDAQ:HRTX – Get Free Report) and AleAnna (NASDAQ:ANNA – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ownership.
Insider and Institutional Ownership
80.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 38.1% of AleAnna shares are held by institutional investors. 5.9% of Heron Therapeutics shares are held by company insiders. Comparatively, 42.9% of AleAnna shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent recommendations for Heron Therapeutics and AleAnna, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Heron Therapeutics | 2 | 0 | 3 | 0 | 2.20 |
| AleAnna | 1 | 0 | 0 | 0 | 1.00 |
Profitability
This table compares Heron Therapeutics and AleAnna’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Heron Therapeutics | -13.04% | N/A | -4.62% |
| AleAnna | 7.19% | 3.31% | 1.93% |
Risk and Volatility
Heron Therapeutics has a beta of 1.7, indicating that its stock price is 70% more volatile than the S&P 500. Comparatively, AleAnna has a beta of -1.59, indicating that its stock price is 259% less volatile than the S&P 500.
Valuation and Earnings
This table compares Heron Therapeutics and AleAnna”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Heron Therapeutics | $154.90 million | 1.61 | -$20.19 million | ($0.13) | -10.19 |
| AleAnna | $25.04 million | 8.38 | $1.80 million | $0.04 | 78.73 |
AleAnna has lower revenue, but higher earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than AleAnna, indicating that it is currently the more affordable of the two stocks.
Summary
AleAnna beats Heron Therapeutics on 8 of the 14 factors compared between the two stocks.
About Heron Therapeutics
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
About AleAnna
AleAnna, Inc. engages in oil and gas exploration and production activities. It focuses on Italy’s natural gas reserves and developing renewable energy solutions. The company was founded in 2007 and is headquartered in Dallas, TX.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
